OBI-3424 is a DNA alkylating cancer therapeutic agent that targets aldo-keto reductase 1C3 (AKR1C3) overexpressing cancers. AKR1C3 overexpression has been known to be found in various treatment-resistant and
Dasiglucagon is a potential first-in-class soluble glucagon analog invented and developed by Zealand. It is in development in the ready-to-use HypoPal rescue pen for easy, fast and effective
The KUBio biomanufacturing facility for BeiGene will be located in Guangzhou in the Chinese province Guangdong, where other biotech firms are setting up operations, said GE. It will
Bonti is focused on developing fast-acting neurotoxin programs intended to be used in aesthetic and therapeutic applications. According to the acquisition terms, the Irish drug maker will make
AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for
Lumoxiti, which is a CD22-directed cytotoxin, has been approved for the patients who had two or prior systemic therapies, including treatment with a purine nucleoside analog. AstraZeneca executive
Praliciguat is an investigational, orally administered soluble guanylate cyclase (sGC) stimulator currently in Phase II clinical trials. Ironwood chief development officer and global development senior vice president Christopher
The trial, dubbed IM011-011, enrolled 267 patients to assess the efficacy and safety of BMS-986165 in comparison to placebo. It delivered significant skin clearance, said the US pharma
Equity for the investment came from Carlyle Asia Partners V, Carlyle’s flagship $6.55 billion Asia fund focused on buyout and strategic investments across a range of sectors in
The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.